Welsh, Carson, Anderson & Stowe, a private equity firm, completed the acquisition of Abzena, a provider of services and technologies for the selection, development, and manufacture of biopharmaceutical products. for £34.4m ($43.7m). "We are pleased to have attracted the long-term support of a specialist investor of the calibre of WCAS. WCAS will provide us with immediate working capital for the business, followed by additional investment, post completion that will enable us to scale up the business and fund further development. We look forward to working with the WCAS team to continue to capitalise on the growing market opportunity for Abzena," John Burt, Abzena CEO.